WO1997046573A1 - Procede d'inhibition du traitement des antigenes, proteines chimeres intervenant dans ce procede, et leurs procedes d'expression - Google Patents
Procede d'inhibition du traitement des antigenes, proteines chimeres intervenant dans ce procede, et leurs procedes d'expression Download PDFInfo
- Publication number
- WO1997046573A1 WO1997046573A1 PCT/US1997/009294 US9709294W WO9746573A1 WO 1997046573 A1 WO1997046573 A1 WO 1997046573A1 US 9709294 W US9709294 W US 9709294W WO 9746573 A1 WO9746573 A1 WO 9746573A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- gly
- dna
- epitope
- ala
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 44
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 18
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 18
- 230000002401 inhibitory effect Effects 0.000 title description 7
- 230000030741 antigen processing and presentation Effects 0.000 title description 6
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical group OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims abstract description 31
- 230000004044 response Effects 0.000 claims abstract description 29
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 230000001404 mediated effect Effects 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 16
- 101710172711 Structural protein Proteins 0.000 claims abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 44
- 108010079364 N-glycylalanine Proteins 0.000 claims description 11
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 2
- 230000000120 cytopathologic effect Effects 0.000 abstract description 2
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 101150089665 EBNA4 gene Proteins 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 210000002950 fibroblast Anatomy 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 108010089610 Nuclear Proteins Proteins 0.000 description 9
- 102000007999 Nuclear Proteins Human genes 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000251477 Chimaera Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 101150059079 EBNA1 gene Proteins 0.000 description 3
- 108010051791 Nuclear Antigens Proteins 0.000 description 3
- 102000019040 Nuclear Antigens Human genes 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000024188 Andala Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101150034762 EBNA3 gene Proteins 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 101710122233 Epstein-Barr nuclear antigen 4 Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- This invention pertains to chimeric nuclear proteins, and methods of expression of the same, which proteins do not trigger a conventional major histocompatibility complex reaction where inserted into a cell of a patient.
- proteins, particularly nuclear proteins, provided with a Gly-Ala repeat domain appear to suppress recognition by cytotoxic T lymphocytes (CTL) and inhibit an induced immune response, interfering with antigen presentation.
- CTL cytotoxic T lymphocytes
- Epstein- Barr virus is a well-studied herpes virus, which transforms cells through expression of episomal DNA in the host cell.
- the same avenue is the basic modality employed in gene therapy, where foreign genetic material is inserted into the cells of the target patient, to achieve expression of that genetic material, producing the therapeutic protein(s) .
- the immune response discussed above includes attack by cytotoxic T lymphocytes (CTL) mediated by the major histocompatibility complex (MHO .
- CTL cytotoxic T lymphocytes
- MHO major histocompatibility complex
- cytotoxic T cells are drawn to, and attack, the foreign material by recognition of the MHC proteins present in response to the inserted foreign or exogenous material.
- proteins, and nuclear proteins in particular are susceptible to MHC Class I- mediated CTL immune response, given the cell surface glycoprotein pattern associated therewith.
- Class II-mediated immune response is also associated with this phenomenon, but not necessarily directly targeted to nuclear proteins.
- the EBV-encoded nuclear antigen EBNA1 is a viral protein regularly detected in all malignancies associated with EBV. See, e.g., Masucci et al . , Trends in Microbiology 2, 125-130 (1994) . No MHC-I mediated CTL response has been demonstrated in connection with this nuclear protein. Rickinson et al .. A New Look at Tumor Immunology, 53-80 (Cold Spring Harbor Laboratory Press, 1992) . If the method by which the MHC-I mediated CTL response to this nuclear protein is inhibited could be adopted for therapeutic proteins, a wide class of proteins could be better utilized for the therapies described.
- Gly-Ala repeat domain is intended herein to mean a series of three tripeptides, wherein each tripeptide consists of Gly and Ala residues. Three triplets define a nine amino acid sequence, which is then repeated. Each triplet contains one Gly, one Ala and a third ammo acid, either Ala or Gly, in any order. The sequence of 3 triplets is repeated in the domain. A total of about 35-50 amino acids appear effective suppressing MHC-I mediated CTL response to the proteins, in "infected cells".
- the domain may be so small as to not sufficiently inhibit toxicity. While the domain may be incorporated m the chimeric protein at any point, it is preferably incorporated downstream of the epitope triggering the
- the Gly-Ala repeat present occupies or "redirects" the mechanism responsible for MHC mediated CTL response to such a degree the epitope-t ⁇ ggered response does not occur possibly due to failure to express foreign protein-induced MHC glycoprotein fragments on the cell surface.
- t intended that the DNA sequence inserted into the sequence encoding the antigen must be inserted so as to encode the repeat itself. That is, the inhibition of the CTL response is a protein-associated phenomenon, not a DNA-associated phenomenon.
- Gly-Ala repeats may be used, if desired. Repeats encoded by DNA segments of up to 700 base pairs have been demonstrated to be effective. Optimal repeat size can be determined by empirical methods, but it appears that 100-130 amino acid domains may be effective in MHC Class-I and perhaps Class-II mediated CTL immune response.
- Figure 1 is a schematic outline of chimaera prepared according to the invention, including a (full-length) EBNA1 chimaera.
- the position of insertion of the EBNA4 416-424 epitope (E4) and the EBNA1 internal repeat region (IR) are indicated by arrows pointing to the amino-acid number in the B95.8 sequence.
- the Gly-Ala repeats are indicated in solid marking, while the nuclear localization signal is dark-shaded, and DNA binding and dimerization domains are indicated by cross-hatching.
- Applicants' invention resides in the discovery that the "infection" by an antigenic protein, of a cell, which would otherwise induce MHC-mediated CTL immune response, can be expressed while inhibiting that response if the expression includes a Gly-Ala repeat domain within the protein.
- the antigenic presentation of the protein, incorporating the Gly-Ala repeats is somehow suppressed, such that CTL response is not triggered.
- the Gly-Ala repeat domain should be on the order of 30 amino acids-150 amino acids. Optimally, it appears that an insertion domain of 50-120 amino acids provides significant inhibition of CTL response.
- the Gly-Ala repeat segment is inserted downstream of that segment of DNA encoding the CTL epitopic portion of the protein, where such is known. Restriction, insertion, ligation, plasmid preparation and cell insertion or "infection" are all conventional technologies familiar to those of ordinary skill in the art, and are not detailed herein, saved for their expression in terms of the examples set forth below.
- the nuclear antigen EBNAl encoded by the EBV is expressed in latent EBV-infected B lymphocytes that persist for life in healthy virus characters, is the only viral protein regularly detected in all malignancies associated with EBV, and not bee demonstrated to be subject to a MHC-mediated CTL response. Mapping of the antigenic protein demonstrated the presence of a Gly-Ala repeat domain, which interferes with antigenic processing and image Class - I, and perhaps Class - II presentation. By fixing the epitope, and inserting the DNA encoding the Gly-Ala repeat downstream of that epitope, CTL recognition of otherwise CTL-recognized epitopes was inhibited.
- EBNAl is a phosphoprotein composed of unique amino and carboxy-terminal domains (amino acids 1-89 and 327-641, respectively, in the prototype B95.8 EBV strain) joined by a repetitive sequence of Arg-Gly-containing motifs, surrounding an internal Gly-Ala repeat. While Gly-Ala repeats of different le-.-gths are present in all EBV isolates and represent the major target of EBNA-specific antibody responses, the specific function of these repeats has not been previously described.
- EBV induces CTL responses.
- Caucasian leukocyte antigen- (HLA)All-positive individuals are often dominated by All- restricted reactivities to peptide epitopes corresponding to residues 399-408 and 416-424 of the EBNA4 protein.
- Dittmar et al Proc. Natl. Acad. Sci. USA, 81,4652-4656 (1984) .
- recombinant vaccinia viruses expressing chimeric genes that contain the EBNA4 416-424 epitope inserted in-frame within the attached EBNAl sequence, or within EBNAl deletion mutants that did not contain the Gly-Ala repeats were prepared.
- EBNAl deletion the native protein with the Gly-Ala repeat domain excised
- EBNA4 416-424 epitope inserted at the His 39, Pro 446 or Lys 520 positions relative to the B95.8 sequence sensitized HLA All-positive fibroblasts to lysis by EBV-specific CTL.
- the level of killing was in each case comparable to that observed after infection with a vaccinia recombinant expressing EBNA4.
- fibroblasts expressing a chimeric full-sized EBNAl with the EBNA4 416-424 epitope inserted at His 39 (E1N-E4) were not recognized by the CTL.
- E1N-E4 and E1 ⁇ GAN-E4 were expressed with slower kinetics and at lower levels compared to the positive orientation E1 ⁇ GAN-E4 whereas the orientation of insertion did not affect the expression of E4IR. It should be noted that the expression of E1N-E4 and E4IR is probably overestimated because of the presence of Gly-Ala-specific antibodies in the human serum.
- Vaccinia recombinants carrying the coding sequences of EBNAl and EBNA4 also known as EBNA-3B
- EBNA-3B Vaccinia recombinants carrying the coding sequences of EBNAl and EBNA4 (also known as EBNA-3B) from B95.8 were used.
- EBNAl (El) or an EBNAl deletion mutant that lacks the Gly-Ala repeat region (E1 ⁇ GA) were produced by inserting an oligonucleotide corresponding to the E4 epitome in the Ncol ,
- PffMl or Bsu361 site of the EBNAl coding sequence (genomic positions: 108,067, 109,291 and 109,510, respectively) .
- the oligonucleotide pairs E1N-E4F/E1N-E4R (5' -CATGCCATAGTAACTGACTTT-
- E4F/E1P-E4R (5' - CGATCGTAACTGACTTTAGTGTAATCAGG- 3 ' /5 ' -
- TTACCTTGATTACACTAAGTCAGTTACGATCG-3 ' were annealed and ligated to appropriately digested pBS-El or pBS-El ⁇ GA at 100:1 ratio ⁇ .
- the pBS-E4IR plasmid was constructed by inserting an
- Ncol-Apal EBNAl fragment (IR, gp: 108,067-109,261) nto the scI site of EBNA4 (gp: 97,302) .
- the E4IR open reading frame was excised by EcoRI and SstI digestion and ligated into pSCll. Insert containing plasmids were sequenced to determine correct orientation and reading frame alignment .
- Recombinant viruses were generated by transfection into CV-I cells infected with WR strain wild- ype vaccinia virus, and recombinant viruses were selected on TK-143 cells. Viral stocks were prepared and titrated in CV-l cells.
- Fibroblast lysis experiments were conducted by growing semiconfluent monolayers of fibroblasts from the donor. These were grown in 96-well plates. Infection was done in the assay wells in the presence of 3 ⁇ Ci sl NaCrOfact per well. CTL clones specific for the EBNA4 416-424 epitope were obtained by stimulation of lymphocytes from an EBV seropositive donor with the autologous B95.8 virus transformed LCL as described in Rickinson et al. supra. The cytotoxic activity was assayed in triplicate in standard four hour 51 Cr-release assays.
- Cell lysis assays were conducted using semiconfluent monolayers of fibroblast, infected and labelled as described above. Aliquots of 5 x 10 6 cells were placed in 5-ml tubes and infected for one hour at 37°C with 1 ml concentrated virus before addition of 2 ml complete medium and further incubation for the indicated times. 100 ⁇ Ci 51 NaCr0 4 were added to each tube two hours before the initiation of the assay.
- the invention is generally applicable to all MHC-mediated CTL response.
- MHC Class-I restricted CTL responses are MHC Class II mediated responses may be similarly inhibited, but since the T cells implicated in such response are generally different from those in Class I responses, the inhibitory effects achieved may be of lower importance .
- modifying proteins to include a Gly-Ala repeat by modifying the DNA encoding the same to include a Gly-Ala repeat domain segment encoding at least about 25-30 amino acids effectively inhibits presentation of the CTL-responsive epitope.
- the repeat sequence is inserted downstream of the CTL-responsive epitope.
- the chimeric proteins, and DNA encoding the same are effectively used in plasmids and other constructs effective in gene therapy, vaccine design and the like, where CTL response would interfere with attempts to employ exogenous proteins in therapy.
- One interesting utility is the modification of autoantigens, or potential autoantigens, expressed by an individual. Individuals (mammals) who are either suffering from autoimmune disease, or at risk to develop autoimmune disease, may be treated by providing them with DNA expressing the autoantigen with a Gly-Ala repeat domain as described. This may be used to render the expressed protein non-i munogenic.
- ADDRESSEE OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT
- NAME OBLON, NORMAN F.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32916/97A AU3291697A (en) | 1996-06-07 | 1997-06-06 | Method of inhibiting antigen processing, chimeric proteins reflecting this method, and methods of expressing those proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66027296A | 1996-06-07 | 1996-06-07 | |
US08/660,272 | 1996-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997046573A1 true WO1997046573A1 (fr) | 1997-12-11 |
WO1997046573A9 WO1997046573A9 (fr) | 1998-04-16 |
Family
ID=24648818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/009294 WO1997046573A1 (fr) | 1996-06-07 | 1997-06-06 | Procede d'inhibition du traitement des antigenes, proteines chimeres intervenant dans ce procede, et leurs procedes d'expression |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3291697A (fr) |
WO (1) | WO1997046573A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022577A1 (fr) * | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Proteines de fusion a demi-vie allongee |
WO2001030378A1 (fr) * | 1999-10-22 | 2001-05-03 | The Walter And Eliza Hall Institute Of Medical Research | Procede de prophylaxie et de traitement |
AU767688B2 (en) * | 1999-10-22 | 2003-11-20 | Walter And Eliza Hall Institute Of Medical Research, The | A method of prophylaxis and treatment |
-
1997
- 1997-06-06 AU AU32916/97A patent/AU3291697A/en not_active Abandoned
- 1997-06-06 WO PCT/US1997/009294 patent/WO1997046573A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
NATURE, 22 June 1995, Vol. 365, LEVITSKAYA et al., "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein Barr Virus Nuclear Antigen-1", pages 685-688. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022577A1 (fr) * | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Proteines de fusion a demi-vie allongee |
WO2001030378A1 (fr) * | 1999-10-22 | 2001-05-03 | The Walter And Eliza Hall Institute Of Medical Research | Procede de prophylaxie et de traitement |
AU767688B2 (en) * | 1999-10-22 | 2003-11-20 | Walter And Eliza Hall Institute Of Medical Research, The | A method of prophylaxis and treatment |
Also Published As
Publication number | Publication date |
---|---|
AU3291697A (en) | 1998-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Levitskaya et al. | Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1 | |
CN100526331C (zh) | 来自ebv的ctl表位 | |
Omar et al. | Syngeneic Marek's disease virus (MDV)-specific cell-mediated immune responses against immediate early, late, and unique MDV proteins | |
Chou et al. | Mapping of herpes simplex virus-1 neurovirulence to γ134. 5, a gene nonessential for growth in culture | |
Britt et al. | Induction of complement-dependent and-independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB) | |
Khanna et al. | Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. | |
US5843456A (en) | Alvac poxvirus-rabies compositions and combination compositions and uses | |
Gavioli et al. | Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4 | |
Hanke et al. | Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides | |
Yaswen et al. | Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein | |
Zarling et al. | Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus | |
Ghiasi et al. | Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge | |
EP0236145A1 (fr) | Procédés de production de glycoprotéines du HCMV, anticorps contre celle-ci et vaccins HCMV, ainsi que des vecteurs recombinants à cet effet | |
Wachsman et al. | Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D | |
Emini et al. | Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein B | |
Salvucci et al. | Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes | |
Kinchington et al. | Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide | |
Zarling et al. | Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine | |
Arnold et al. | Transgenic mice expressing a soluble foreign H-2 class I antigen are tolerant to allogeneic fragments presented by self class I but not to the whole membrane-bound alloantigen. | |
Khanna et al. | Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells | |
Cohen et al. | Varicella-zoster virus open reading frame 1 encodes a membrane protein that is dispensable for growth of VZV in vitro | |
Sievers et al. | Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules | |
WO1995016779A1 (fr) | Proteine icp4 du virus de l'herpes du type 2 et son utilisation dans une composition de vaccin | |
EP0747481B1 (fr) | Peptides du virus d'Epstein-Barr et anticorps dirigés contre ces peptides | |
WO1997046573A1 (fr) | Procede d'inhibition du traitement des antigenes, proteines chimeres intervenant dans ce procede, et leurs procedes d'expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGE 1/1, DRAWINGS, REPLACED BY A NEW PAGE BEARING THE SAME NUMBER; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98500714 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |